Novonesis: Still Too Expensive
Source: SeekingAlpha
2025-02-06 00:20:58 ET
Summary
- Novonesis, formed from Novozymes and Christian Hansen, is a strong business with stable margins and high ROIC, but recent growth rates have declined.
- Despite solid Q3/24 results, NVZMF's long-term growth has slowed, though management and analysts expect future acceleration in revenue and margin improvements.
- Intrinsic value calculations suggest the stock is not a bargain unless very optimistic growth assumptions are met, indicating cautious investment is advised.
- Novonesis remains a great long-term investment with a wide economic moat, but it's crucial to avoid overpaying for its shares.
Aside from the rather famous company Novo Nordisk A/S ( NVO ) from Denmark, there are a few other Danish companies worth mentioning as they also have a wide economic moat around the business and were great investments in the past. One of these companies is Novonesis A/S (NVZMF) (NVZMY) which is the result of a merger of Novozymes and Christian Hansen....
Read the full article on Seeking Alpha
For further details see:
Novonesis: Still Too Expensive
Novozymes A/S ADR
NASDAQ: NVZMY
NVZMY Trading
0.83% G/L:
$54.55 Last:
27,606 Volume:
$54.70 Open:
